A Phase 1/2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway
收藏NIAID Data Ecosystem2026-03-14 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2751259
下载链接
链接失效反馈官方服务：
资源简介：
This is a Phase 1/2, open-label, multicenter, study evaluating the safety, tolerability, PK, PD, and anti-tumor activity of MRTX0902 alone and in combination with MRTX849 (adagrasib) in patients with advanced solid tumor malignancy harboring mutations in the KRAS, MAPK pathways.
创建时间：
2022-11-15
